Progress in the Management of Early-Stage Non-Small Cell Lung Cancer in 2017.
Donington, Jessica S. MD, MSCR a,*; Kim, Young Tae MD, PhD b; Tong, Betty MD, MS, MHS c; Moreira, Andre L. MD, PhD d; Bessich, Jamie MD e; Weiss, Kathleen D. MD f; Colson, Yolonda L. MD, PhD f; Wigle, Dennis MD, PhD g; Osarogiagbon, Raymond U. MBBS h; Zweig, Jeffrey MD i; Wakelee, Heather MD i; Blasberg, Justin MD j; Daly, Megan MD k; Backhus, Leah MD l; Van Schil, Paul MD m
Journal of Thoracic Oncology.
13(6):767-778, June 2018.
(Format: HTML, PDF)
: The landscape of care for early-stage non-small cell lung cancer continues to evolve. While some of the developments do not seem as dramatic as what has occurred in advanced disease in recent years, there is a continuous improvement in our ability to diagnose disease earlier and more accurately. We have an increased understanding of the diversity of early-stage disease and how to better tailor treatments to make them more tolerable without impacting efficacy. The International Association for the Study of Lung Cancer and the Journal of Thoracic Oncology publish this annual update to help readers keep pace with these important developments. Experts in the care of early-stage lung cancer patients have provided focused updates across multiple areas including screening, pathology, staging, surgical techniques and novel technologies, adjuvant therapy, radiotherapy, surveillance, disparities, and quality of life. The source for information includes large academic meetings, the published literature, or novel unpublished data from other international oncology assemblies.
Copyright (C) 2018 by the International Association for the Study of Lung Cancer